Inotersen: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany) and HAS (France) recommended or restricted inotersen, while CONITEC (Brazil) and DMC (Denmark) did not recommend it.
The record spans 4.9 years, opening at G-BA (Germany) on 22 Mar 2019 and running to 11 Feb 2024.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), PHARMAC (New Zealand) and AWMSG (Wales) among them — hold no record for inotersen at all.
Not every gap is a refusal: for inotersen, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 2 of 7 records date from 2023 or later.
G-BA (Germany) was first to assess inotersen, on 22 Mar 2019; NYE METODER (Norway) did not open a file until 11 Feb 2024 — a wide spread of 4.9 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 7 dated records fall in 2019 alone.
HAS (France) is the only agency to have returned to inotersen, recording 2 separate entries.
6 of the 18 agencies in this archive hold a record for inotersen.
The full ledger for inotersen reads 2 not recommended, 2 recommended, 1 other and 1 withdrawn, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 11 Feb 2024 | Behandling av polynevropati i stadium 1 eller 2 hos voksne pasienter medhereditær transtyretin amyloidose (hATTR). | decision recorded | source |
| CONITEC (Brazil) | 11 May 2023 | Tratamento da polineuropatia amiloidótica familiar relacionada à transtirretina em pacientes adultos Não atendidos pela … | not incorporated | source |
| DMC (Denmark) | 9 Dec 2020 | Arvelig transthyretin-medieret amyloidose (hATTR) | Ikke anbefalet | source |
| HAS (France) | 4 Sep 2019 | Listing (Transparency Committee) | SMR substantial · ASMR IV | source |
| SMC (Scotland) | 12 Aug 2019 | For the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). | withdrawn | source |
2 further decisions for inotersen, across 2 agencies, are not shown here. They link to 1 further source document.
Related molecules
- ibrutinib — also decided by NYE METODER in 2024Q1
- vestronidase alfa — also decided by NYE METODER in 2024Q1
- maribavir — also decided by NYE METODER in 2024Q1
- risdiplam — also decided by NYE METODER in 2024Q1
- fenfluramine — also decided by NYE METODER in 2024Q1
- lebrikizumab — also decided by NYE METODER in 2024Q1
Coverage: 7 decisions for inotersen from 6 agencies, 2019 to 2024. Data to 7 Sep 2026. ATC class N07 — Other nervous system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.